STOCK TITAN
  1. Home
  2. News
  3. CMMB

Chemomab Therapeutics Ltd - CMMB STOCK NEWS

Welcome to our dedicated news page for Chemomab Therapeutics (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chemomab Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chemomab Therapeutics's position in the market.

News
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced the early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis (PSC). The company expects to report topline data from the PSC clinical trial by midyear 2024, rather than in the second half of 2024 as previously projected. CM-101 is a first-in-class monoclonal antibody with dual anti-inflammatory and anti-fibrotic activity, and it has Orphan Drug designation for PSC in the U.S. and the European Union (EU), as well as Fast Track designation by the U.S. Food & Drug Administration (FDA).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
clinical trial
-
News
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) reports on its study analyzing serum samples and clinical data from systemic sclerosis (SSc) patients, revealing high serum CCL24 levels associated with severe manifestations of the disease, including pulmonary arterial hypertension (PAH). The company's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.22%
Tags
none
-
News
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has been granted Fast Track designation by the FDA for CM-101, a first-in-class monoclonal antibody designed to treat primary sclerosing cholangitis (PSC), a fibrotic liver disease. The Phase 2 SPRING trial is advancing towards completion of enrollment with the top-line readout expected in 2H 2024. CM-101's unique dual anti-fibrotic and anti-inflammatory activity has demonstrated potential disease-modifying effects in preclinical and early clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.93%
Tags
clinical trial
News
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) reported on proteomic analyses of Phase 2a liver fibrosis clinical data and oral presentation of proteomic analyses in PSC patients at AASLD's The Liver Meeting® 2023. The data showed consistent and significant improvements in liver-related pathology pathways after treatment with CM-101, a monoclonal antibody designed to neutralize CCL24, a key driver of inflammatory and fibrotic processes underlying PSC and other disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
clinical trial
-
News
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) reported strong progress in advancing the CM-101 Phase 2 PSC trial towards completion of enrollment, on track for topline readout in the second half of 2024. The company reiterated that cash reserves are sufficient to fund operations through the end of 2024, with decreasing quarterly cash burn expected to continue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
earnings
-
News
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) received a notice from the Nasdaq Listing Qualifications Department stating that the company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of its American Depositary Shares (ADSs) on the Nasdaq Capital Market. The company has until May 6, 2024, to regain compliance by having the closing bid price of its ADSs meet or exceed $1.00 per ADS for at least 10 consecutive business days. The company's ADSs will continue to trade on the Nasdaq Capital Market under the symbol 'CMMB'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
none
News
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update
Rhea-AI Summary
Chemomab Therapeutics Ltd. will release its third quarter 2023 financial results and a business update on November 9, 2023 at 8:00 am Eastern Time. Investors can contact the company at IR@chemomab.com for further discussion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
conferences earnings
-
News
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
Rhea-AI Summary
Chemomab Therapeutics to present at major U.S. scientific conferences in November
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference
Rhea-AI Summary
Chemomab Therapeutics announces positive developments for CM-101 in the treatment of primary sclerosing cholangitis (PSC). Phase 2 SPRING trial progressing with topline data expected in H2 2024. CM-101 demonstrates dual anti-fibrotic and anti-inflammatory activity. Positive results from Phase 2a trial in NASH patients. Promising potential as a disease-modifying therapy for PSC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
News
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
earnings
Stock CMMB logo
Chemomab Therapeutics Ltd

Nasdaq:CMMB

CMMB Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CMMB Stock Data

10.93M
187.84M
14.99%
24.96%
1.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Tel Aviv

About CMMB

chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).